Novogen spikes on JV's ovarian cancer discovery
25 November, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) shares grew more than 18% after the company announced its new JV has discovered that lead drug candidate Trilexium can destroy ovarian cancer spheroids.
Biotron gets ethics nod for HCV trial
21 November, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) has received ethics approval for a three-month trial of the new capsule formulation of antiviral drug BIT225 in hepatitis C patients.
Supporting Indigenous health and wellbeing
20 November, 2013A philanthropic donation of $10 million for Indigenous health has been gifted to the University of Western Australia.
Patrys wins new Aussie patent for cancer antibody
19 November, 2013 by Dylan Bushell-EmblingPatrys has been granted a second Australian patent - its seventh globally - covering anticancer antibody PAT-SM6.
Novogen, Genea testing drugs for genetic diseases
15 November, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has teamed with Genea biocells to test a line of compounds which are effective against cancer stem cells in a range of genetic and degenerative disorders.
2013 Research Australia Awards winners announced
14 November, 2013The 2013 Research Australia Awards, held last night at the Park Hyatt in Melbourne, recognised individuals and corporations for areas such as discovery, advocacy, philanthropy and lifetime achievement.
Dramatic increase in diabetes unveiled
14 November, 2013A surge in diabetes is occurring in Australia, and across the world, according to the latest IDF Diabetes Atlas.
TGA approves Gliolan brain surgery drug
12 November, 2013 by Dylan Bushell-EmblingThe TGA has approved the local availability of Gliolan, a drug for helping brain surgeons remove tumours, through licensee Specialised Therapeutics Australia.
Patrys's SM6 bound for new myeloma trial
11 November, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) shares climbed 66% after the company announced a new combination study for one of its anticancer antibodies and the award of a US patent for another.
Government vetoes cap on self-education expenses
07 November, 2013The federal government will not go ahead with a proposed cap on self-education expenses.
Novogen forms ovarian cancer JV
07 November, 2013 by Dylan Bushell-EmblingA joint venture between Novogen (ASX:NRT) and Yale University will focus on developing ovarian cancer drugs, eventually including personalised chemotherapeutic treatments.
Patrys antibody awarded orphan drug status in US
07 November, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) now has orphan drug status for antibody PAT-SM6 in multiple myeloma covering the US as well as the EU.
NHMRC recognises researchers' hard work
04 November, 2013The NHMRC has recognised a human molecular geneticist and an IVF researcher with the respective NHMRC Outstanding Contribution Award and the NHMRC Ethics Award.
Prana shares surge on Alzheimer's study results
01 November, 2013 by Dylan Bushell-EmblingShares in Prana Biotechnology (ASX:PBT) climbed 43% after a scientific paper detailed how Alzheimer's drug candidate PBT2 reversed cognitive and memory loss in old mice.
Alchemia gets $8.8m R&D tax rebate for FY13
30 October, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has received an $8.8m R&D tax incentive windfall, as it benefited from a finding that it can apply for a rebate on some research conducted overseas.
